Search research articles
Contact Us
Filters
Showing results (171-180 of 192) with videos related to
Page
of 20
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 18, 2002
Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity
Mark D Lacy, Jason D Maguire, Mazie J Barcus, et al.
The Lancet. Infectious Diseases
|
September 10, 2022
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies
Helen S Marshall, Timo Vesikari, Peter C Richmond, et al.
Antimicrobial Agents and Chemotherapy
|
April 16, 2008
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum
Rajeev K Mehlotra, Gabriel Mattera, Moses J Bockarie, et al.
Anesthesiology
|
March 19, 2025
Inhibition of Endoplasmic Reticulum Oxidoreductin 1 Modulates Neuronal Excitability and Nociceptive Sensitivity in Mice
Aislinn D Maguire, Shawn M Lamothe, Muhammad Saad Yousuf, et al.
Vaccine
|
July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months
Lars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Vaccine
|
March 4, 2000
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
T P Le, K M Coonan, R C Hedstrom, et al.
The Lancet. Child & Adolescent Health
|
June 18, 2026
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial
Lars Ostergaard, Hanna Czajka, Lilia Roque-Guerrero, et al.
Annals of Tropical Medicine and Parasitology
|
January 23, 2003
Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia
J D Maguire, M D Lacy, Sururi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2001
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia
J K Baird, M D Lacy, H Basri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2002
Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia
Judith Ling, J Kevin Baird, David J Fryauff, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 192) with videos related to
Sort By:
Page
of 20
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 18, 2002
Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity
Mark D Lacy, Jason D Maguire, Mazie J Barcus, et al.
The Lancet. Infectious Diseases
|
September 10, 2022
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies
Helen S Marshall, Timo Vesikari, Peter C Richmond, et al.
Antimicrobial Agents and Chemotherapy
|
April 16, 2008
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum
Rajeev K Mehlotra, Gabriel Mattera, Moses J Bockarie, et al.
Anesthesiology
|
March 19, 2025
Inhibition of Endoplasmic Reticulum Oxidoreductin 1 Modulates Neuronal Excitability and Nociceptive Sensitivity in Mice
Aislinn D Maguire, Shawn M Lamothe, Muhammad Saad Yousuf, et al.
Vaccine
|
July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months
Lars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Vaccine
|
March 4, 2000
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
T P Le, K M Coonan, R C Hedstrom, et al.
The Lancet. Child & Adolescent Health
|
June 18, 2026
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial
Lars Ostergaard, Hanna Czajka, Lilia Roque-Guerrero, et al.
Annals of Tropical Medicine and Parasitology
|
January 23, 2003
Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia
J D Maguire, M D Lacy, Sururi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2001
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia
J K Baird, M D Lacy, H Basri, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2002
Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia
Judith Ling, J Kevin Baird, David J Fryauff, et al.
Page
of 20